# Aerin Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aerin-medical

- Industry: Medical Devices & Equipment
- Headquarters: Austin, US
- Website: www.aerinmedical.com/
- Total disclosed funding: $128M
- Latest round: Series G (Dec 13, 2024)
- Investors on record: 8

## About

Aerin Medical, Inc. is a US-based company specializing in innovative treatment solutions for nasal conditions. They focus on providing non-invasive procedures to alleviate symptoms related to Nasal Airway Obstruction and chronic rhinitis.Founded in 2011 and headquartered in Austin, Texas, Aerin Medical develops proprietary technologies for nasal treatments. The company has successfully raised USD 32.48 mn in Series G funding as of December 13, 2024, which will support its operations and development efforts. The CEO, Matt Brokaw, leads the company, which has completed 9 deals to date.Aerin Medical specializes in innovative treatment solutions for nasal conditions, particularly focusing on Nasal Airway Obstruction (NAO) and chronic rhinitis. Their core products include VivAer® and RhinAer®, non-invasive options utilizing temperature-controlled radiofrequency technology designed to provide long-lasting relief from congestion, breathing difficulties, and chronic rhinitis symptoms. These procedures are conducted in medical settings, making them convenient for patients and seamlessly integrating into existing clinical practices. The primary customer base comprises healthcare providers across the United States.Aerin Medical generates revenue by providing specialized medical procedures directly to healthcare providers through B2B transactions. Physicians and clinics perform treatments using Aerin Medical's proprietary technology and may enter into partnerships with healthcare facilities offering VivAer® and RhinAer® treatments. The firm's revenue model revolves around procedure-based pricing, allowing healthcare providers to charge patients directly for the treatments, supported by the clinical benefits of its technology.In December 2024, Aerin Medical, Inc. raised USD 32.48 mn in Series G funding, co-led by KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation from Ares Capital. The company plans to utilize this funding to enhance its operations and further develop its product offerings. While specific new products are not detailed, the company is likely focused on expanding its reach within the current market and potential new geographic regions.

## Funding rounds

- Series G, Dec 13, 2024, $32M — OrbiMed Advisors, Ares Capital, Ally Bridge Group, Questa Capital, KCK MedTech
- Series F, Apr 28, 2022, $35M — OrbiMed Advisors, Ally Bridge Group, KCK Group, Questa Capital
- Series E, Aug 4, 2020, $50M — OrbiMed Advisors, KCK Group, Questa Capital
- Series C, Mar 8, 2016, $11M — Targeted Technology, KCK Group
- Seed, Nov 30, 2011, $0.1M — LaunchCapital

## Investors

- LaunchCapital (https://capitalatlas.ai/funds/launchcapital) — Seed
- Targeted Technology (https://capitalatlas.ai/funds/targeted-technology) — Series C
- KCK Group — Series C, Series E, Series F
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series E, Series F, Series G
- Questa Capital (https://capitalatlas.ai/funds/questa-capital) — Series E, Series F, Series G
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series F, Series G
- Ares Capital — Series G
- KCK MedTech (https://capitalatlas.ai/funds/kck-medtech) — Series G